Hillsdale Investment Management Inc. cut its position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 19.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 94,400 shares of the medical instruments supplier’s stock after selling 23,000 shares during the period. Hillsdale Investment Management Inc. owned approximately 0.16% of OraSure Technologies worth $1,629,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. Alps Advisors Inc. raised its stake in OraSure Technologies by 0.3% during the second quarter. Alps Advisors Inc. now owns 43,257 shares of the medical instruments supplier’s stock worth $747,000 after purchasing an additional 111 shares during the period. PNC Financial Services Group Inc. raised its stake in OraSure Technologies by 0.5% during the first quarter. PNC Financial Services Group Inc. now owns 46,588 shares of the medical instruments supplier’s stock worth $602,000 after purchasing an additional 242 shares during the period. Profund Advisors LLC raised its stake in OraSure Technologies by 2.8% during the second quarter. Profund Advisors LLC now owns 10,903 shares of the medical instruments supplier’s stock worth $188,000 after purchasing an additional 293 shares during the period. Timber Hill LLC raised its stake in OraSure Technologies by 3.2% during the second quarter. Timber Hill LLC now owns 11,597 shares of the medical instruments supplier’s stock worth $200,000 after purchasing an additional 363 shares during the period. Finally, Wellington Management Group LLP raised its stake in OraSure Technologies by 0.5% during the first quarter. Wellington Management Group LLP now owns 111,970 shares of the medical instruments supplier’s stock worth $1,448,000 after purchasing an additional 587 shares during the period. 92.10% of the stock is currently owned by institutional investors.

A number of equities analysts have commented on OSUR shares. Jefferies Group LLC lifted their target price on shares of OraSure Technologies from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, June 28th. Canaccord Genuity lifted their target price on shares of OraSure Technologies from $15.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, June 28th. BidaskClub downgraded shares of OraSure Technologies from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 24th. Zacks Investment Research raised shares of OraSure Technologies from a “hold” rating to a “buy” rating and set a $24.00 target price on the stock in a research note on Saturday, September 9th. Finally, Stephens reaffirmed an “overweight” rating and set a $19.00 target price (up from $14.00) on shares of OraSure Technologies in a research note on Tuesday, July 11th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $18.04.

Shares of OraSure Technologies, Inc. (NASDAQ OSUR) traded down 1.06% during trading on Thursday, reaching $22.47. 32,161 shares of the company’s stock were exchanged. OraSure Technologies, Inc. has a 52 week low of $7.09 and a 52 week high of $22.79. The stock has a 50 day moving average price of $20.72 and a 200-day moving average price of $16.18. The stock has a market capitalization of $1.34 billion, a price-to-earnings ratio of 41.53 and a beta of 1.57.

OraSure Technologies (NASDAQ:OSUR) last released its earnings results on Wednesday, August 2nd. The medical instruments supplier reported $0.09 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.07 by $0.02. OraSure Technologies had a net margin of 22.29% and a return on equity of 15.64%. The business had revenue of $40.18 million for the quarter, compared to analysts’ expectations of $36.54 million. During the same period last year, the company earned $0.07 earnings per share. The company’s quarterly revenue was up 28.1% on a year-over-year basis. Analysts predict that OraSure Technologies, Inc. will post $0.48 earnings per share for the current year.

In related news, EVP Anthony Zezzo II sold 72,916 shares of the firm’s stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $21.26, for a total value of $1,550,194.16. Following the sale, the executive vice president now directly owns 218,326 shares of the company’s stock, valued at $4,641,610.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Brian Smith sold 9,112 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $20.47, for a total transaction of $186,522.64. Following the completion of the sale, the insider now directly owns 32,477 shares in the company, valued at $664,804.19. The disclosure for this sale can be found here. Insiders sold 669,678 shares of company stock worth $13,886,419 over the last three months. Corporate insiders own 6.40% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Hillsdale Investment Management Inc. Has $1.63 Million Holdings in OraSure Technologies, Inc. (OSUR)” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/09/28/hillsdale-investment-management-inc-has-1-63-million-holdings-in-orasure-technologies-inc-osur.html.

About OraSure Technologies

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Institutional Ownership by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Stock Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related stocks with our FREE daily email newsletter.